513 related articles for article (PubMed ID: 7880375)
41. The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines.
Hall MD; Amjadi S; Zhang M; Beale PJ; Hambley TW
J Inorg Biochem; 2004 Oct; 98(10):1614-24. PubMed ID: 15458824
[TBL] [Abstract][Full Text] [Related]
42. Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia.
Burchenal JH; Kalaher K; O'Toole T; Chisholm J
Cancer Res; 1977 Sep; 37(9):3455-7. PubMed ID: 884687
[TBL] [Abstract][Full Text] [Related]
43. Preparation of antitumor oxaliplatin/cisplatin docking dinuclear platinum complex.
Noji M; Kizu R; Takeda Y; Akiyama N; Yoshizaki I; Eriguchi M; Kidani Y
Biomed Pharmacother; 2005 Jun; 59(5):224-9. PubMed ID: 15919175
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
46. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
Farrell N; Kelland LR; Roberts JD; Van Beusichem M
Cancer Res; 1992 Sep; 52(18):5065-72. PubMed ID: 1516063
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
48. Cytotoxicity and tolerance to DNA adducts of alicyclic mixed amine platinum(II) homologs in tumor models sensitive and resistant to cisplatin or tetraplatin.
Yoshida M; Khokhar AR; Siddik ZH
Oncol Rep; 1998; 5(5):1281-7. PubMed ID: 9683851
[TBL] [Abstract][Full Text] [Related]
49. Toxicity and anti-tumor activity of hydrophobic diammine and diaminocyclohexane platinum complexes entrapped in multilamellar vesicles.
Khokhar AR; Al-Baker S; Perez-Soler R
Anticancer Drug Des; 1988 Dec; 3(3):177-84. PubMed ID: 3207465
[TBL] [Abstract][Full Text] [Related]
50. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.
Mailliet P; Segal-Bendirdjian E; Kozelka J; Barreau M; Baudoin B; Bissery MC; Gontier S; Laoui A; Lavelle F; Le Pecq JB
Anticancer Drug Des; 1995 Jan; 10(1):51-73. PubMed ID: 7695813
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes.
Khokhar AR; al-Baker S; Siddik ZH
J Inorg Biochem; 1994 Apr; 54(1):39-47. PubMed ID: 8151310
[TBL] [Abstract][Full Text] [Related]
52. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Nicolson MC; Orr RM; O'Neill CF; Harrap KR
Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
[TBL] [Abstract][Full Text] [Related]
53. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
54. New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin.
Ramos-Lima FJ; Quiroga AG; García-Serrelde B; Blanco F; Carnero A; Navarro-Ranninger C
J Med Chem; 2007 May; 50(9):2194-9. PubMed ID: 17407274
[TBL] [Abstract][Full Text] [Related]
55. Antitumor effects of a new lipophilic platinum compound, trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)platinum(IV), in mice.
Saegusa Y; Eriguchi M; Kidani Y; Matsuzawa A; Takeda Y
Anticancer Res; 2001; 21(1A):245-52. PubMed ID: 11299742
[TBL] [Abstract][Full Text] [Related]
56. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity and cross-resistance studies with Pt-ascorbato complexes.
Hrubisko M; Balázová E; Kiss F; Kovácová J; Ujházy V
Neoplasma; 1989; 36(6):651-7. PubMed ID: 2615869
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II).
Wilkoff LJ; Dulmadge EA; Trader MW; Harrison SD; Griswold DP
Cancer Chemother Pharmacol; 1987; 20(2):96-100. PubMed ID: 3664938
[TBL] [Abstract][Full Text] [Related]
59. Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II).
Macquet JP; Cros S; Armand JP
Cancer Res; 1984 Sep; 44(9):3736-43. PubMed ID: 6540142
[TBL] [Abstract][Full Text] [Related]
60. [Antitumor activity of a new platinum complex, (R)-(-)-2-aminomethylpyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II), against cisdiamminedichloroplatinum (II)-resistant murine leukemia cell line].
Akamatsu K; Endo K; Matsumoto T; Kamisango K; Morikawa K; Koizumi M; Mitsui H; Koizumi K; Matsuno T
Gan To Kagaku Ryoho; 1990 Jan; 17(1):73-8. PubMed ID: 2404458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
